By specifically inducing CD40 stimulation in the presence of FAP, this novel bispecific antibody was demonstrated to overcome the systemic toxicity associated with the CD40 agonist, thereby providing a promising approach for cancer immunotherapy. Here, CD40 is linked to cancer.